Pellepharm Inc. may have come up with a "Goldilocks drug" – just enough, not too much – to treat Gorlin syndrome, its chief medical officer (CMO), Ervin Epstein, told BioWorld, as the company finished the third closing of a $20 million series B financing and disclosed positive top-line data from a phase II trial with topical hedgehog inhibitor patidegib.